Resistance to meropenem-vaborbactam in clinical isolates of Enterobacter roggenkampii without previous exposure to vaborbactam.

作者信息

Navarro-Carrera Paula, García-Clemente Paloma, Gómez-Gil Rosa, Cáceres-Sánchez Rubén, Bloise Iván, Dahdouh Elias, Moreno-Ramos Francisco, García-Rodríguez Julio, Mingorance Jesús, Lázaro-Perona Fernando

机构信息

Servicio de Microbiología, Hospital Universitario La Paz, IdiPAZ, Paseo de La Castellana, Madrid, Spain.

Servicio de Farmacia, Hospital Universitario La Paz, Paseo de La Castellana, Madrid, Spain.

出版信息

Clin Microbiol Infect. 2022 Dec;28(12):1662-1664. doi: 10.1016/j.cmi.2022.09.005. Epub 2022 Sep 20.

DOI:10.1016/j.cmi.2022.09.005

PMID:36150673

Abstract

摘要

相似文献

Resistance to meropenem-vaborbactam in clinical isolates of Enterobacter roggenkampii without previous exposure to vaborbactam.

Clin Microbiol Infect. 2022 Dec;28(12):1662-1664. doi: 10.1016/j.cmi.2022.09.005. Epub 2022 Sep 20.

Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an Hollow-Fiber Model.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01969-17. Print 2018 Feb.

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.

Int J Antimicrob Agents. 2021 Nov;58(5):106439. doi: 10.1016/j.ijantimicag.2021.106439. Epub 2021 Sep 20.

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01659-18. Print 2019 Jan.

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.

Infect Dis Ther. 2020 Dec;9(4):757-767. doi: 10.1007/s40121-020-00350-1. Epub 2020 Oct 5.

Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant .

Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02048-18. Print 2019 Mar.

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Isolates Collected in U.S. Hospitals during 2016 to 2018.

Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01951-19.

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).

J Antimicrob Chemother. 2021 Sep 15;76(10):2600-2605. doi: 10.1093/jac/dkab252.

In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.

J Antimicrob Chemother. 2018 Oct 1;73(10):2789-2796. doi: 10.1093/jac/dky251.

In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.

Diagn Microbiol Infect Dis. 2019 Mar;93(3):258-260. doi: 10.1016/j.diagmicrobio.2018.09.017. Epub 2018 Oct 4.

引用本文的文献

Characterizing carbapenemase-producing isolates from Spain: high genetic heterogeneity and wide geographical spread.

Front Cell Infect Microbiol. 2024 May 16;14:1390966. doi: 10.3389/fcimb.2024.1390966. eCollection 2024.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验